Compare Eli Lilly And Co (LLY) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

SHY, a US stock, trades at $81.955, down 0.04% on the day. Technical indicators show a bullish overall signal with bearish moving averages and neutral oscillators, while key support and resistance levels cluster around $82. Recent corporate actions include scheduled dividend payments of $0.24 per share through mid-2026, indicating stable income distribution.

The outlook for SHY is mixed, with technical momentum facing near-term resistance. Investment opportunities center on dividend consistency, but risks include market volatility and sensitivity to interest rate changes. Investors should weigh income stability against potential price stagnation amid evolving macroeconomic conditions.